Combination / selection rationale: 5-ALA and iron have different roles in heme synthesis. A capsule study combined 5-ALA phosphate with sodium ferrous citrate (SFC), requiring separate control of ALA salt identity, ALA reporting basis and iron source.
Published evidence / source details: The 2023 ALADDIN trial randomized 100 participants with sarcopenia to five groups for 12 weeks. Regimens used reported ALA-phosphate amounts of 50/100/150 mg and SFC amounts of 29/57 mg; all groups also received zinc yeast. The primary week-12 skeletal-muscle-mass-index endpoint did not differ significantly between groups, while some grip-strength and other secondary measures improved.
Development insights: Confirm molecular weight, assay and ALA equivalent for the actual supplied salt, then calculate SFC and elemental iron separately: SFC mass is not elemental-iron mass. Premix ALA, iron and low-level partners separately for capsule trials, assessing assay uniformity, moisture, colour, disintegration and packaged stability, with an iron-matched control.
Evidence scope: A study of a specific phosphate-based formulation, not evidence of this ingredient’s treatment effect or hydrochloride equivalence. Published amounts are not intake recommendations.
2023 · Tamura et al. · ALADDIN study · DOI 10.3390/nu15132866 ↗